CO-AMP-ROBOTICS-CORP
19.7.2021 10:02:11 CEST | Business Wire | Press release
AMP Robotics Corp. (“AMP”), a pioneer in AI, robotics, and infrastructure for the waste and recycling industry, is expanding its presence in Europe as demand grows for the company’s AI and automation solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210719005207/en/
AMP has appointed REP-TEC Advanced Technologies , specialists in the supply, installation, and support of recycling equipment, as an official reseller and integrator for customers in the United Kingdom and Ireland. In addition, to further support the expansion of its business in Europe, AMP has hired Gary Ashburner as its European General Manager to build out the company’s infrastructure across the region. Based in the UK, Ashburner leads customer and partner acquisition, pre- and post-sales consulting, system design, supply, installation, training, and service.
“We’re seeing greater interest in and adoption of our technology in the U.S., with customers reordering our AI-guided robotic sorting systems to install in other facilities that they own. This is generating a robust pipeline in the U.S. that’s being mirrored internationally, following the installation of our first robotic sorting system in Europe late last year,” said Ashburner. “We share a commitment to improving global resource efficiency and productivity with REP-TEC, and look forward to working with an established leader that also embraces new technology and innovation as we extend our efforts to modernize and expand recycling infrastructure in Europe and globally.”
AMP’s European expansion reflects strong year-over-year revenue growth and investment in operational scale made possible by its latest funding round of USD $55 million at the beginning of the year. The company’s AI platform, AMP Neuron™, encompasses the largest known real-world dataset of recyclable materials for machine learning , with the ability to classify more than 100 different categories and characteristics of recyclables across single-stream recycling, e-scrap, and construction and demolition debris, and reaching an object recognition run rate of more than 10 billion items annually.
“We’re delighted to partner with AMP Robotics and support the company’s growth across the UK and Ireland,” said Colm Grimes, CEO of REP-TEC. “We recognize the desire to add AI and robotics to Europe’s recycling infrastructure and believe AMP has developed a system that will change the economics of this industry. We’ll be installing our first three AMP Cortex™ high-speed sorting systems later this summer. This will provide a great UK reference site with the ability to run material trials for interested parties.”
To further its market penetration, AMP is actively seeking to establish additional reseller partnerships in Belgium, The Netherlands, Luxembourg, Germany, and France.
About AMP Robotics™ Corp.
AMP Robotics is modernizing the world’s recycling infrastructure by applying AI and automation to increase recycling rates and economically recover recyclables reclaimed as raw materials for the global supply chain. The AMP Cortex™ high-speed robotics system automates the identification and sorting of recyclables from mixed material streams. The AMP Neuron™ AI platform continuously trains itself by recognizing different colors, textures, shapes, sizes, patterns, and even brand labels to identify materials and their recyclability. Neuron then guides robots to pick and place the material to be recycled. Designed to run 24/7, all of this happens at superhuman speed with extremely high accuracy. AMP Clarity™ provides data and material characterization on what recyclables are captured and missed, helping recycling businesses and producers maximize recovery. With deployments across North America, Asia, and Europe, AMP’s technology recovers recyclables from municipal collection, precious commodities from electronic scrap, and high-value materials from construction and demolition debris.
About REP-TEC
REP-TEC was formed with a vision to improve global resource efficiency through automation and harnessing new waste recycling technologies. REP-TEC are specialists in the design, manufacture, installation, and support of a range of recycling solutions. The REP-TEC portfolio includes fully automatic balers, conveyor systems, compactors, and the AMP Cortex™ high-speed robotics systems. REP-TEC is passionate about innovation and exploring clients’ workstreams to uncover opportunities for significant efficiency improvements. With coverage throughout the UK and Ireland, REP-TEC provides nationwide aftersales service and support that meets the most demanding Service Level Agreements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210719005207/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release
Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
